BREMEN, Germany,
Sept. 26, 2017/PRNewswire/ --
Brukertoday announced the closing of its acquisition of
MERLIN Diagnostika GmbH,位于德国波恩。梅林有深入expertise in products, services and consulting in the fields of antibiotic resistance testing (ART) and antibiotic susceptibility testing (AST). MERLIN's technology and product portfolio for human and veterinary antibiotic resistance and specialty susceptibility testing further expands Bruker´s microbiology business, which is based on rapid, broad-based microbial identification using
Bruker'smarket-leadingMALDI Biotyper(MBT)platform for proteomic fingerprinting. Financial details were not disclosed.
The principle of the MERLINMICRONAUT™system for specialty susceptibility testing is the phenotypic detection of microbial growth inhibition in the presence of antibiotics. Its microdilution procedure is a standardized, globally accepted reference method for the determination of minimal inhibitory concentrations (MICs). Standard and special AST plates are available for in-vitro diagnostic use according to the EU directive EC/98/79 for a wide spectrum of clinically important microorganisms. MERLIN's focus is on the detection of major resistance phenotypes, i.e. MRSA, VRE, MBL, ESBL, KPC, AMP-C, and OXA-48. In addition, MERLIN has the ability to customize antibiograms for more than 200 antibiotics. Due to this flexibility, theMICRONAUTsystem enables laboratories to adjust their testing profiles to the rapid spread of certain new resistances.MICRONAUTsoftware for identification and susceptibility testing includes an expert plausibility check, and has for several years already offered an interface to Bruker´sMALDI Biotyper.
MERLIN is a member of the
German Diagnostic Industry Association(VDGH) and the Paul-Ehrlich-Society for Chemotherapy (www.p-e-g.org), and MERLIN is involved in various studies related to antibiotic resistance, e.g. the monitoring of drug resistance among clinically relevant pathogens in
Germanyand central
Europe. For such multicenter studies involving human and veterinary medicine, MERLIN offers the design and production of dedicated MIC study plates, as well as scientific consulting and support. MERLIN acts as a reference laboratory for annual inter-laboratory tests by the INSTAND organization (www.instand-ev.de) for quality assurance in microbiology.
MERLIN will continue to serve all existing collaboration and distribution partners, as well as all OEM customers and end customers after the acquisition.
Dr.
Esther Pfeil, Managing Director of
MERLIN Diagnostika GmbH, commented: "We are very pleased to be part of Bruker´s microbiology business now, as we have been collaborating with
Brukeralready for several years. Our product and service offerings in the field of antibiotic susceptibility testing (AST) complement theMALDI Biotypersystem for fast and efficient microbial identification. With our proven expertise in the field of AST, we aim to accelerate further assay additions to theMBT-STAR™ consumables portfolio for selected, rapid antibiotic resistance and susceptibility testing on theMALDI Biotyper."
Dr.
Johann-Wolfgang Wittke, Managing Director of the Medical Laboratory Bremen (
Germany实验室),说:“我们一直在与无条件转移ker´sMALDI Biotyperfor microbial identification and theMICRONAUTsystem from MERLIN for many years. TheMICRONAUTmicrodilution approach with the determination of true minimal inhibitory concentrations has leading analytical performance and reliability. We use MERLIN's custom-tailored microtiter plates to answer different microbiological questions, or for the detection of resistance mechanisms. This flexibility is unmatched in the market, and I am looking forward to further integration, synergies and reduction of hands-on time."
Dr.
Wolfgang Pusch, Executive Vice President for Microbiology & Diagnostics at Bruker Daltonics, added: "MERLIN adds expertise and an impressive portfolio of flexible specialty products for antibiotic susceptibility testing to
Bruker'sclinical and applied microbiology business. Over time, we expect that MERLIN will further expand our selected, high-value ART and AST assay portfolio for theMALDI Biotyper."
About the
BrukerMALDI Biotyper(MBT) Platform
TheMALDI Biotyperfamily of systems enables molecular identification of microorganisms like bacteria, yeasts and fungi. Classification and identification of microorganisms is achieved reliably and quickly using proteomic fingerprinting by high-throughput MALDI-TOF mass spectrometry. TheMALDI Biotyperuses a molecular approach based on specific proteomic fingerprints from bacterial strains. Many published studies have highlighted the greater accuracy and lower cost offered, as well as typically much faster time-to-result (TTR).
Applications of variousMALDI Biotypersolutions include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product safety and quality control, as well as marine microbiology. In many European and international laboratories theMALDI Biotyperhas replaced classical biochemical testing for bacterial identification in the past few years due to the accuracy, speed, extensive species coverage, ease of use and cost effectiveness of the system. Traditional biochemical techniques detect different metabolic properties of microorganisms, can take many hours or even days for completion, and they often lack specificity.
The robustMALDI Biotyperrequires minimal sample preparation and offers low consumables cost. The products of theMALDI Biotyperfamily are available in a research-use-only (RUO) version, as the U.S.
FDA-clearedMALDI Biotyper CA System, or in an IVD-CE version according to EU directive EC/98/79. TheMALDI Biotyperalso has medical device registrations in numerous other countries. RUO versions of theMALDI Biotyperallow selected, high-value antimicrobial resistance tests.
About
Bruker Corporation(NASDAQ: BRKR)
For more than 55 years,
Brukerhas enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life.
Bruker'shigh-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers,
Brukeris enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, nano-analysis and industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research, clinical microbiology and molecular pathology research. For more information, please visit:www.energie2point0.com
Investor Contact:
Miroslava Minkova
Head of Investor Relations
T: +1 (978) 663–3660, ext. 1479
E:miroslava.minkova@bruker.com
Contact for Media and Customers:
Dr.
Wolfgang Pusch
Bruker Daltonics Division
Tel: +49-421-2205-270
E:Wolfgang.Pusch@bruker.com
MALDI Biotyper®and MBT STAR®are registered trademarks of
Bruker Daltonik GmbHin the
European Unionand other regions.
View original content with multimedia:http://www.prnewswire.com/news-releases/bruker-announces-acquisition-of-merlin-to-add-selected-antibiotic-resistance-and-susceptibility-testing-to-its-maldi-biotyper-microbial-identification-platform-300525262.html
SOURCE
Bruker Corporation